---
title: "Universe Pharmaceuticals (UPC) news: delisting"
url: "https://aibio.space/companies/universe-pharmaceuticals/"
publisher: "aibio.space (Biotech Investor Relations News)"
summary: "UPC delisting news: Universe Pharmaceuticals gets Nasdaq delisting notice over delayed Form 20-F. Universe Pharmaceuticals Inc (NASDAQ: UPC), China."
---

UPC Universe Pharmaceuticals Inc NASDAQ · China

# Universe Pharmaceuticals (UPC) news UPC delisting news

Listings · 2026-10-06

## [Universe Pharmaceuticals holders approve conditional 10-into-1 share consolidation](https://aibio.space/news/universe-pharmaceuticals-holders-approve-conditional-10-1-share/)

A 10-into-1 share consolidation takes effect only if the Class A bid price is below $1.00 for three consecutive trading days within 12 months. The 6-K gives no current share price and does not say whether Nasdaq has sent a notice.

## Latest Universe Pharmaceuticals news

1. 2025-07-03 Financings [Universe Pharmaceuticals reports $3.3 million six-month loss, cash of $47,272,851](https://aibio.space/news/universe-pharmaceuticals-reports-3-3-million-six-month-loss-cash-47/) The net loss widened to $3.3 million as third-party sales fell. Cash rose to $47,272,851, mainly because of a $15,000,000 share issue and related-party borrowings.
2. 2025-02-25 Listings [Universe Pharmaceuticals gets Nasdaq delisting notice over delayed Form 20-F](https://aibio.space/news/universe-pharmaceuticals-gets-nasdaq-delisting-notice-delayed-form-20/) The company is already before a Nasdaq Hearings Panel over a separate rule, 5550(a)(2). It says it will ask for a stay of the suspension and is working on the report.
3. 2025-01-27 Distress [Universe Pharmaceuticals says its 20-F will be late, expects $20.33 million net loss](https://aibio.space/news/universe-pharmaceuticals-says-20-f-will-late-expects-20-33-million-net/) The company expects a net loss of about $20.33 million for the year ended September 30, 2024, up from $6.16 million a year earlier.

## Universe Pharmaceuticals at a glance

- **Ticker**: UPC

- **Listing**: NASDAQ

- **Country**: China

- **Cash, Sep 30, 2025**: $33.59 billion

### Related companies

- [Shanxi C&Y Pharmaceutical Group Co.](https://aibio.space/companies/shanxi-c-y-pharmaceutical/) SZSE: 300254
- [China SXT Pharmaceuticals](https://aibio.space/companies/china-sxt-pharmaceuticals/) NASDAQ: SXTC
- [Shanghai Bao Pharmaceuticals Co](https://aibio.space/companies/shanghai-bao-pharmaceuticals/) HKEX: 2659
- [Chimin Health Management Co.](https://aibio.space/companies/chimin-health-management/) SSE: 603222
- [Jiangxi Fushine Pharmaceutical Co.](https://aibio.space/companies/jiangxi-fushine-pharmaceutical/) SZSE: 300497
- [Tibet Rhodiola Pharmaceutical Holding Co.](https://aibio.space/companies/tibet-rhodiola-pharmaceutical/) SSE: 600211
- [China National Accord Medicines Corporation](https://aibio.space/companies/china-national-accord-medicines/) SZSE: 000028
- [Hainan Shuangcheng Pharmaceuticals Co.](https://aibio.space/companies/hainan-shuangcheng-pharmaceuticals/) SZSE: 002693

### Also on NASDAQ

- [Coya Therapeutics](https://aibio.space/companies/coya-therapeutics/) COYA
- [Tango Therapeutics](https://aibio.space/companies/tango-therapeutics/) TNGX
- [Enanta Pharmaceuticals](https://aibio.space/companies/enanta-pharmaceuticals/) ENTA
- [Beam Therapeutics](https://aibio.space/companies/beam-therapeutics/) BEAM
- [Fennec Pharmaceuticals](https://aibio.space/companies/fennec-pharmaceuticals/) FENC
- [SpyGlass Pharma](https://aibio.space/companies/spyglass-pharma/) SGP

## Universe Pharmaceuticals annual financials

| Line | FY ended Sep 30, 2025 | FY ended Sep 30, 2024 |
|---|---|---|
| Revenue | [$17.86 billion](https://www.sec.gov/Archives/edgar/data/1809616/000121390026009000/) | [$23.02 billion](https://www.sec.gov/Archives/edgar/data/1809616/000121390026009000/) |
| Research and development | [$671.8 million](https://www.sec.gov/Archives/edgar/data/1809616/000121390026009000/) | [$3.03 billion](https://www.sec.gov/Archives/edgar/data/1809616/000121390026009000/) |
| Net income (loss) | [-$3.67 billion](https://www.sec.gov/Archives/edgar/data/1809616/000121390026009000/) | [-$8.73 billion](https://www.sec.gov/Archives/edgar/data/1809616/000121390026009000/) |
| Cash from operations | [-$5.05 billion](https://www.sec.gov/Archives/edgar/data/1809616/000121390026009000/) | [-$9.51 billion](https://www.sec.gov/Archives/edgar/data/1809616/000121390026009000/) |
| Cash and equivalents | [$33.59 billion](https://www.sec.gov/Archives/edgar/data/1809616/000121390026009000/) | [$29.50 billion](https://www.sec.gov/Archives/edgar/data/1809616/000121390026009000/) |

Latest balance sheet, Sep 30, 2025 (20-F): cash and equivalents $33.59 billion.

Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice.

## Questions about Universe Pharmaceuticals

Was Universe Pharmaceuticals delisted?

Our latest story on this, dated Feb 25, 2025: "Universe Pharmaceuticals gets Nasdaq delisting notice over delayed Form 20-F". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/universe-pharmaceuticals-gets-nasdaq-delisting-notice-delayed-form-20/).

What is the ticker symbol of Universe Pharmaceuticals?

Universe Pharmaceuticals Inc trades under the ticker UPC on NASDAQ.

Where is Universe Pharmaceuticals listed?

Universe Pharmaceuticals Inc is listed on NASDAQ.

What is the SEC CIK of Universe Pharmaceuticals?

The SEC Central Index Key (CIK) for Universe Pharmaceuticals Inc is 1809616. Its filings are on SEC EDGAR.

How many shares does Universe Pharmaceuticals have outstanding?

563,338 shares as of 2025-09-30, per the cover page of its 20-F filed 2026-01-29.

Which country or territory is Universe Pharmaceuticals listed under?

Our directory records Universe Pharmaceuticals Inc under China.

What does Universe Pharmaceuticals do?

Our directory classifies Universe Pharmaceuticals Inc as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.

What is the ISIN of Universe Pharmaceuticals?

The ISIN recorded for Universe Pharmaceuticals Inc is KYG9442G1385.

Does aibio.space cover Universe Pharmaceuticals?

aibio.space lists Universe Pharmaceuticals Inc among 2,820 public biotech companies and publishes its news here as stories appear.

Where is Universe Pharmaceuticals incorporated?

SEC records list its state or country of incorporation as F4.

What was Universe Pharmaceuticals's revenue last year?

$17.86 billion for the fiscal year ended Sep 30, 2025, as reported to the SEC.

Is Universe Pharmaceuticals profitable?

Universe Pharmaceuticals Inc reported a net loss of $3.67 billion for the fiscal year ended Sep 30, 2025, and used $5.05 billion of cash in operations, per its annual report to the SEC.

How much does Universe Pharmaceuticals spend on research and development?

$671.8 million in the fiscal year ended Sep 30, 2025, per its annual report.

How much cash does Universe Pharmaceuticals have?

$33.59 billion in cash at Sep 30, 2025, per its 20-F.

What is the latest Universe Pharmaceuticals (UPC) stock news?

Our latest story on Universe Pharmaceuticals, dated Oct 6, 2026: "Universe Pharmaceuticals holders approve conditional 10-into-1 share consolidation". A 10-into-1 share consolidation takes effect only if the Class A bid price is below $1.00 for three consecutive trading days within 12 months. The 6-K gives no current share price and does not say whether Nasdaq has sent a notice. [Source](https://aibio.space/news/universe-pharmaceuticals-holders-approve-conditional-10-1-share/).

## Investor discussion: Universe Pharmaceuticals

Members talk about Universe Pharmaceuticals (UPC). Reader posts, not aibio.space reporting, and not investment advice.

Rules

1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
2. **Say whether you hold the stock.** Every post states long, short or no position.
3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you.
4. **No buy or sell calls and no price targets.**
5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them.
6. **No personal details and no spam.** No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion).

## Capital-markets timeline

Financings, listing notices, splits, legal actions and other investor events at Universe Pharmaceuticals, newest first. Each line links the filing it comes from.

1. 2026-10-06 Listings Reported a reverse stock split. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1809616/000121390026107197/ea0307745-6k_universe.htm)
2. 2026-09-01 Listings Reported a reverse stock split. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1809616/000121390026096306/ea030394401ex99-1.htm)
3. 2026-05-14 Listings Reported a reverse stock split. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1809616/000121390026056617/ea0290821-6k_universe.htm)
4. 2025-07-03 Financings Reported a financing. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1809616/000121390025061480/ea0246983-6k_universe.htm)
5. 2025-03-20 Listings Reported a reverse stock split. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1809616/000121390025025300/ea023461001ex99-1_universe.htm)
6. 2025-03-11 Listings Reported a reverse stock split. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1809616/000121390025022737/ea0233926-6k_universe.htm)
7. 2025-02-25 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1809616/000121390025017079/ea023172101ex99-1_universe.htm)
8. 2025-02-11 Listings Reported a reverse stock split. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1809616/000121390025012207/ea023067301ex99-1_universe.htm)
9. 2025-02-03 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1809616/000121390025009434/ea022930001ex99-1_universe.htm)
10. 2025-01-30 Listings Reported a reverse stock split. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1809616/000121390025008083/ea022911501ex99-1_universe.htm)
11. 2025-01-27 Distress Told the SEC a periodic report would be filed late. SEC Form NT 20-F. [Source](https://www.sec.gov/Archives/edgar/data/1809616/000121390025006745/ea0228773-nt20f_universe.htm)
12. 2024-11-13 Listings Reported a reverse stock split. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1809616/000121390024097143/ea022084201ex99-1_universe.htm)
13. 2024-11-01 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1809616/000121390024093481/ea021966001ex99-1_universe.htm)

## Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:UPC on TradingView](https://www.tradingview.com/symbols/NASDAQ-UPC/).

## SEC filings and registration

- **SEC name**: Universe Pharmaceuticals INC

- **CIK**: 1809616

- **Industry (SIC)**: Pharmaceutical Preparations (2834)

- **US tickers**: UPC (Nasdaq)

- **State or country of incorporation**: F4

- **Fiscal year ends**: September 30

- **Filer category**: Non-accelerated filer<br>Emerging growth company

- **Business address**: 265 JINGJIU AVENUE, JI'AN, JIANGXI, China, 343100

- **Phone**: 86-0796-8403309

- **Shares outstanding**: 563,338 as of 2025-09-30 (20-F filed 2026-01-29)

### Recent filings (8-K and 6-K are the company's own announcements)

- [6-K](https://www.sec.gov/Archives/edgar/data/1809616/000121390026107197/ea0307745-6k_universe.htm) filed 2026-10-06
- [6-K](https://www.sec.gov/Archives/edgar/data/1809616/000121390026096306/ea0303944-6k_universe.htm) filed 2026-09-01
- [6-K](https://www.sec.gov/Archives/edgar/data/1809616/000121390026083956/ea0299724-6k_universe.htm) filed 2026-07-31
- [6-K](https://www.sec.gov/Archives/edgar/data/1809616/000121390026082789/ea0299049-6k_universe.htm) filed 2026-07-29
- [6-K](https://www.sec.gov/Archives/edgar/data/1809616/000121390026072603/ea0295794-6k_universe.htm) filed 2026-06-26
- [6-K](https://www.sec.gov/Archives/edgar/data/1809616/000121390026056617/ea0290821-6k_universe.htm) filed 2026-05-14
- [6-K](https://www.sec.gov/Archives/edgar/data/1809616/000121390026044641/ea0286657-6k_universe.htm) filed 2026-04-16
- [6-K](https://www.sec.gov/Archives/edgar/data/1809616/000121390026014886/ea0276581-6k_universe.htm) filed 2026-02-11

Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001809616), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices.

## Listing details

Universe Pharmaceuticals Inc is a public biotech or pharmaceutical company listed on NASDAQ under the ticker UPC, recorded under China. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

- **Company**: Universe Pharmaceuticals Inc

- **Ticker**: UPC

- **Listing**: NASDAQ

- **Country or territory**: China

- **Business scope**: Pharmaceuticals: Major

- **ISIN**: KYG9442G1385

- **Last quote in directory**: 2026-10-21

- **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-UPC/)

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/).

Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/).

Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update)

---
Source page: https://aibio.space/companies/universe-pharmaceuticals/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Universe Pharmaceuticals (UPC) news: delisting", 2026-10-31, https://aibio.space/companies/universe-pharmaceuticals/